Newswise — JULY 10, 2023, NEW YORK – A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to better outcomes in esophageal cancer patients treated with a combination of chemotherapy and immunotherapy, or immunochemotherapy. Esophageal cancer is the sixth leading cause of cancer mortality worldwide, and the incidence of esophageal adenocarcinoma has been climbing at a relatively swift clip over the past 40 years. Survival times for inoperable or metastatic forms of the cancer range from 6 to 12 months.
Led by Ludwig Oxford Director Xin Lu and former graduate student Thomas Carroll and published in the current issue of the journal Cancer Cell, the study also shows that the degree to which a tumor’s malignant cells are mutated is similarly predictive of survival outcomes. Further, combining measurement of tumor mutational burden (TMB) and tumor monocyte content (TMC) better predicts treatment response than either measurement alone. This suggests that the combined measurement is a potential biomarker for the selection of patients likely to benefit from immunochemotherapy.
“Some cancer patients respond to treatment while some do not, and still others respond only partially,” said Lu. “The challenge is to understand why certain people fall into each category and identify the molecular bases of their heterogeneous responses.”
A clinical trial (LUD2015-005) launched in 2015 by Ludwig Oxford offered a unique opportunity to address this challenge. The 35 patients with inoperable esophageal adenocarcinoma enrolled in this trial, unlike those in many others, received four weeks of immunotherapy with immune checkpoint inhibitors (ICI) alone (either anti-PD-L1, or anti-PD-L1 and anti-CTLA-4) before undergoing 18 weeks of combination immunochemotherapy.
Both healthy and cancerous biopsies were collected from the patients at multiple time points and from multiple sites over the course of their treatment. The researchers then performed single cell RNA sequencing (scRNA-seq) on 65,000 cells from a subset of the clinical trial patients to generate a detailed cellular atlas of the upper gastrointestinal tract, which served as a reference map of all the cell types that can be found in esophageal cancers.
Due to technical and other challenges associated with scRNA-seq—which analyzes the RNA output of individual cells—such analysis was only performed on 8 of the 35 EAC patients in the clinical trial. However, the biopsies of all patients underwent bulk RNA sequencing, a much more cost-effective alternative.
The team then used computational methods—deconvolution algorithms—to determine with high confidence the proportion of different cell types in each biopsy. Deconvolution is a computational tool that combines the biological insights from scRNA and bulk RNA sequencing while compensating for the particular weaknesses of each method—high cost and low resolution, respectively.
"In clinical research, we have to find ways to get as much information as possible from each precious sample. In this case, we wanted to use single-cell sequencing on a subset of those samples to gain detailed insight into the cell composition of these tumors, and combine that knowledge with the statistical power of conducting bulk RNA sequencing on everyone. That's what deconvolution attempts to do,” explained Carroll.
Deconvolution revealed that the number of monocytes in the tumor before treatment was the most reliable predictor of outcome. This finding was surprising because ICI primarily targets the immune system’s T cells, which lead the assault on tumors. “We found that pre-treatment T cell markers are not at all useful in predicting long-term patient outcomes for the treatment used in this trial,” Carroll said.
The researchers hypothesize that the patients with high TMC can generate more pro-inflammatory immune cells from the monocytes in response to ICI therapy than patients with low TMC. Supporting this, they found that after four weeks of ICI, TMC-high patients showed a higher level of dendritic cells and M1 macrophages, which elicit pro-inflammatory or "tumor-killing" responses, while TMC-low patients had more anti-inflammatory or "tumor-supporting" M2 macrophages.
“We don't have the formal demonstration of this yet, and that's where the future research will be,” Lu said.
Using publicly available data, the team also confirmed that the link between high TMC and improved outcomes held for the most common forms of gastric cancer as well.
Aside from identifying the combination of TMB and TMC as potential biomarkers for response to immunochemotherapy, the researchers report that expression of PD-L1—a protein targeted by ICI in the clinical trial—is not a good predictor of patient outcomes for such therapies. They also identify a novel T cell inflammation signature (INCITE) that correlates with ICI-induced tumor shrinkage. This signature could serve as a general indicator of a patient’s responsiveness to immunotherapy, irrespective of their cancer.
This study was supported by Ludwig Cancer Research, Cancer Research UK, the Oxford Experimental Cancer Medicine Centre, AstraZeneca UK Ltd (drug supply) and the National Institute for Health and Care Research Oxford Biomedical Research Centre.
Aside from her Ludwig post, Xin Lu is a professor of cancer biology at the University of Oxford and director of the Oxford Centre for Early Cancer Detection (OxCODE).
# # #
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 50 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested nearly $3 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the seventh year running, and number 2 in the QS World Rankings 2022. At the heart of this success are the twin pillars of our ground-breaking research and innovation and our distinctive educational offer.
Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalized approach to teaching sparks imaginative and inventive insights and solutions.
Through its research commercialization arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years. The University is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing £15.7 billion to the UK economy in 2018/19, and supports more than 28,000 full-time jobs.
RSS